Tuesday, 11 August 2020

Eli Lilly enters into alliance with Dexcom

18 December 2019 | News

To Integrate Dexcom CGM into Personalized Diabetes Management System

image credit- shuttershock.com

image credit- shuttershock.com

Eli Lilly and Company has announced a global commercialization agreement to integrate DexCom, Inc. products into Lilly's personalized diabetes management system, currently in development to advance the treatment of diabetes. Under the terms of the non-exclusive agreement, Lilly will use Dexcom's continuous glucose monitoring (CGM) devices in both the pen- and pump-based platforms of the system being designed to help improve diabetes management.

The agreement with Dexcom builds on Lilly's efforts to provide a comprehensive system that integrates connected insulin delivery devices, software and analysis to equip people with type 1 and type 2 diabetes and their healthcare providers with personalized information and guidance to help simplify management of their diabetes.

"Even with all of the advances in diabetes technology, insulin therapy is still overwhelming and complex," said Mike Mason, senior vice president, Connected Care and Insulins, Lilly Diabetes. "We're excited to include Dexcom's technology in the solutions we deliver to people with diabetes to help improve health outcomes by delivering actionable insights in one connected system. As we integrate our expertise and insights with those from our partners, like Dexcom, we are aiming to not only transform the way we develop and deliver medicine, but to transform how people manage their diabetes."

The personalized diabetes management system being developed will include both pen- and pump-based platforms. The goal of the pen-based platform is to integrate personalized data from a prefilled, disposable insulin pen with data from glucose-sensing technologies into a compatible software application. Personalized data is transferred from the pen via an optional attachment. The goal of the pump-based platform, which is a hybrid-closed loop system, is to use integrated devices – an insulin pump, continuous glucose monitor and a dedicated handheld controller or smartphone application that controls the system – to automate insulin dosing.

"CGMs provide people with diabetes and their healthcare team with important real-time data that can help alleviate the burden of diabetes management, including overall glucose level trends and information on time spent in target blood glucose range," said Rick Doubleday, executive vice president and chief commercial officer of Dexcom. "We're looking forward to expanding our collaboration with Lilly as we integrate our technology into their system and believe it will help reduce some of the complexity that can come from managing diabetes every day."


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account